Drugs / VP-14637
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01355016 | Sep → Nov 2011 | respiratory syncytial virus infectious disease | MicroDose Therapeutx, Inc | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01556607 Comparator | Mar → May 2012 | — | MicroDose Therapeutx, Inc | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2011-04-20 | Gilead Sciences | Gilead and MicroDose Therapeutx Announce License and Collaboration Agreement to Develop MDT-637 for Treatment of Respiratory Syncytial Virus gilead.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VP-14637 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297402 ↗ |
| Known as | MDT-637 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01556607 ↗ |
| Modality | Small molecule | — CHEMBL4297402 ↗ |
| Route | Inhaled | “Inhaled doses of MDT-637 over a 24 hour period” NCT01355016 ↗ |